Prebiotic-Based Nanoamorphous Atorvastatin Attenuates Nonalcoholic Fatty Liver Disease by Retrieving Gut and Liver Health
文献类型：期刊论文
| 作者 | Cui,Jin-Jin; Li,Rui; Ma,Xiao-Lei; Yu,Hao-Yang; Luo,Zhi-Gang; Du,Peng; Ren,Ling; Ding,Xiao; Guo,Xiu-Ping; Zheng,Wen-Sheng |
| 刊名 | SMALL STRUCTURES
 |
| 出版日期 | 2023 |
| 页码 | 2200312 |
| 关键词 | atorvastatin gut flora nanoamorphous nonalcoholic fatty liver disease prebiotics SOLID DISPERSIONS STATIN USE EFFICACY STEATOHEPATITIS FORMULATION SAFETY ABSORPTION ACTIVATION MICROBIOTA CIRRHOSIS |
| ISSN号 | 2688-4062 |
| DOI | 10.1002/sstr.202200312 |
| 英文摘要 | The pathogenesis of nonalcoholic fatty liver disease (NAFLD) is multifactorial and composite, with the disorder of lipid metabolism-induced lipotoxicity being one of the main risk factors. Atorvastatin (AT), the most widely prescribed lipid-lowering drug, has pleiotropic actions benefiting NAFLD treatment. However, low absorption rate in the gut and potential disruption of AT on gut flora hindered its further applications. Notably, gut dysbiosis is involved in and is thus a promising management strategy for NAFLD. In this study, we constructed a prebiotic-based AT nanoamorphous (PANA) to improve the efficacy of AT against NAFLD by retrieving liver and gut health. After oral administration, PANA showed superior drug accumulation in the liver tissue compared with pure AT. Moreover, PANA intervention effectively restored gut healthiness, indicated by reconstructed gut flora, and improved intestinal immunity, barrier integrity, and inflammation. Consequently, compared with AT, PANA treatment caused profound inhibition of weight gain and fat deposition, decreased plasma lipid levels, and alleviated hepatic steatosis and liver inflammation. The transcriptome analysis in the gut and liver tissues identified improved immunity and inflammation as potential mechanisms. This study suggests a promising strategy to treat NAFLD, assisted with nanotechnology in synergy with functional biomaterials. |
| 学科主题 | Chemistry ; Science & Technology - Other Topics ; Materials Science |
| WOS记录号 | WOS:000916661900001 |
| 源URL | [http://ir.kib.ac.cn/handle/151853/75547]  |
| 专题 | 中国科学院昆明植物研究所 |
| 推荐引用方式 GB/T 7714 | Cui,Jin-Jin,Li,Rui,Ma,Xiao-Lei,et al. Prebiotic-Based Nanoamorphous Atorvastatin Attenuates Nonalcoholic Fatty Liver Disease by Retrieving Gut and Liver Health[J]. SMALL STRUCTURES,2023:2200312. |
| APA | Cui,Jin-Jin.,Li,Rui.,Ma,Xiao-Lei.,Yu,Hao-Yang.,Luo,Zhi-Gang.,...&Wang,Lu-Lu.(2023).Prebiotic-Based Nanoamorphous Atorvastatin Attenuates Nonalcoholic Fatty Liver Disease by Retrieving Gut and Liver Health.SMALL STRUCTURES,2200312. |
| MLA | Cui,Jin-Jin,et al."Prebiotic-Based Nanoamorphous Atorvastatin Attenuates Nonalcoholic Fatty Liver Disease by Retrieving Gut and Liver Health".SMALL STRUCTURES (2023):2200312. |
入库方式： OAI收割
来源：昆明植物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。